Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.87 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.87 |
| ▸ | PRKD3 | O94806 | 15/20 | 0.87 |
| ▸ | PRKCG | P05129 | 15/20 | 0.87 |
| ▸ | PRKCB | P05771 | 15/20 | 0.87 |
| ▸ | PRKCA | P17252 | 15/20 | 0.87 |
| ▸ | PRKCH | P24723 | 15/20 | 0.87 |
| ▸ | PRKCI | P41743 | 15/20 | 0.87 |
| ▸ | PRKCE | Q02156 | 15/20 | 0.87 |
| ▸ | PRKCZ | Q05513 | 15/20 | 0.87 |
| ▸ | PRKCD | Q05655 | 15/20 | 0.87 |
| ▸ | PRKD1 | Q15139 | 15/20 | 0.87 |
| ▸ | PRKACA | P17612 | 14/20 | 0.87 |
| ▸ | PRKACB | P22694 | 14/20 | 0.87 |
| ▸ | PRKACG | P22612 | 13/20 | 0.87 |
| ▸ | EGFR | P00533 | 13/20 | 0.87 |
| ▸ | SRC | P12931 | 3/20 | 0.87 |
| ▸ | PLK4 | O00444 | 1/20 | 0.82 |
| ▸ | STK25 | O00506 | 1/20 | 0.82 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108144 | 1.00 | PRKCQ (0.87) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL14342272 | 1.00 | PRKCQ (0.87) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL13529583 | 0.93 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL13497846 | 0.93 | PRKCQ (0.82) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL22765188 | 0.93 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL21312651 | 0.92 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL29595097 | 0.92 | PRKCQ (0.81) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL22765529 | 0.92 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL22765530 | 0.92 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCB | |
| SCHEMBL22765538 | 0.92 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224194-A1 | Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-09-15 | — | — | US | disclosed |
| CN-101703509-A | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG | 2010-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224194-A1 | Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity | FLT3, MCL1, STK25 | PRKCQ 276/4885ROCK2 1215/4885PRKD3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.